Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for preventing and treating cerebral infarction

A composition and technology of cerebral infarction, applied in the field of medicine, can solve the problems of slow onset of effect and general therapeutic effect, and achieve the effect of no side effects, good therapeutic effect and high safety

Active Publication Date: 2020-01-10
JIAMUSI UNIVERSITY
View PDF9 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there are many drugs for the treatment of cerebral infarction, especially traditional Chinese medicines, but the therapeutic effect is average and the effect is slow

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing and treating cerebral infarction
  • Pharmaceutical composition for preventing and treating cerebral infarction
  • Pharmaceutical composition for preventing and treating cerebral infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 The protective effect of the pharmaceutical composition on the model of hypoxia and glucose deficiency of nerve cells

[0033] Cell culture: Take the frozen PC12 cell line and resuscitate it in a centrifuge tube, centrifuge to get the supernatant, suspend it with RPMI1640 medium containing 10% FBS, inoculate it in a petri dish, culture and pass in an incubator, and grow in logarithm Harvest the cells at period, adjust the concentration to 1×10 by suspending in medium 4 cells / ml were plated in 24-well plates for subsequent experiments.

[0034] Experimental grouping: normal control group, continue to pass through 95% O 2 and 5% CO 2 The mixed gas; the second group is the OGD model group: PC12 cells remove the normal culture medium and replace it with glucose-free HBSS solution (140mM NaCl, 3.5mMKCl, 12mM MgSO 4, 5mM NaHCO 3 ,1.7mM CaCl 2 ,0.4mM KH 2 PO 4 , 10mM Hepes), put into a dedicated anoxic tank, and pass through 95% N 2 and 5% CO 2 In the treat...

Embodiment 2

[0048] Embodiment 2: The influence of medicine on rat cerebral ischemia-reperfusion model

[0049] experiment material

[0050] Animals: healthy Wistar rats, domesticated in the animal breeding room for more than 3 days, all male, weighing 180-220 g, a total of 80 rats.

[0051] experiment method

[0052] Wistar rats were anesthetized with isoflurane (3% for introduction, 2% for maintenance) using anesthesia to dissect the right carotid artery by median incision, and after the common carotid and external carotid arteries were threaded, they were temporarily blocked Blood flow in the common and external carotid arteries. An embolus was inserted from the external carotid artery, and after cutting the external carotid artery, it was inserted 10.5 mm into the internal carotid artery from the bifurcation of the external carotid artery and the internal carotid artery, and the start of the middle cerebral artery was closed to close the surgical wound. The rectal temperature of the...

Embodiment 3

[0067] Embodiment 3: pharmaceutical composition tablet of the present invention

[0068] Weigh 8g of cortex base, 16g of paeoniflorin, mix well, add 160g of sodium hydroxymethyl cellulose, 50g of dextrin, pass through a 16-mesh sieve to make wet granules, dry the wet granules at 50-60°C, and dry the granules with a 20-mesh Sieve for granulation, add 2% magnesium stearate, mix well, and press into tablets with a weight of 0.2g / tablet.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition. The pharmaceutical composition is prepared from phellodendrine, paeoniflorin and optional EGCG (epigallocatechin gallate). The pharmaceutical composition can prevent or treat brain tissue damage caused by local and whole cerebral ischemia, can specifically prevent or treat cerebral hemorrhage, cerebral infarction, cerebral thrombosis and otherdiseases, especially has a very good treatment effect on cerebral infarction, and is high in safety and free from side effect.

Description

technical field [0001] The present invention relates to the field of medicine, in particular, the present invention relates to a pharmaceutical composition comprising Phellodendriline, Paeoniflorin and optionally EGCG, a preparation method, and an application thereof for preventing and treating cerebral infarction. Background technique [0002] Cerebral infarction, also known as ischemic stroke, refers to the localized ischemic necrosis or softening of brain tissue caused by cerebral blood supply disturbance, ischemia, and hypoxia. The common clinical types of cerebral infarction include cerebral thrombosis, lacunar infarction, and cerebral embolism. Cerebral infarction accounts for 80% of all strokes. . Cerebral infarction not only poses a great threat to human health and life, but also brings great pain and heavy burden to patients, families and society. [0003] After the onset of cerebral infarction, under the action of various pathophysiological mechanisms, neuronal c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61K31/7048A61K31/353A61P9/10
CPCA61K31/353A61K31/4375A61K31/7048A61P9/10A61K2300/00
Inventor 杨慧李洪滨陈伟达
Owner JIAMUSI UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com